Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients
December 10, 2015 07:30 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced updated plans to begin clinical development...
Vitae Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference
November 24, 2015 16:15 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
November 18, 2015 16:15 ET
|
Vitae Pharmaceuticals, Inc.
Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers
Robust ex vivo biomarker response, suppressing secretion of...
REMINDER: Vitae Pharmaceuticals to Host Analyst and Investor Briefing
November 12, 2015 16:30 ET
|
Vitae Pharmaceuticals, Inc.
Scheduled for 7:00 a.m. EST on November 19, 2015
Presentations to begin at 7:15 a.m. EST
FORT WASHINGTON, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a...
Vitae Pharmaceuticals to Present at Stifel 2015 Healthcare Conference
November 10, 2015 16:30 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
November 05, 2015 16:05 ET
|
Vitae Pharmaceuticals, Inc.
Announces psoriasis as lead indication for VTP-43742
Conference call scheduled for 4:30 p.m. EST today
FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc....
Vitae Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 5, 2015
November 02, 2015 16:30 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, November 5, 2015 at...
Vitae Pharmaceuticals to Host Analyst and Investor Briefing
October 20, 2015 08:00 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday,...
Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors
September 30, 2015 16:15 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D.,...
Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients
September 29, 2015 06:30 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated the second part of its...